Skip to main content

Advertisement

SpringerLink
Log in

Molecular determinants of folate levels after leucovorin administration in colorectal cancer

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

Oral leucovorin (LV) is used with uracil/tegafur (UFT) in the treatment of colorectal cancer (CRC). In order to find the factors related to the efficacy of LV in enhancing the antitumour effect of UFT, we investigated the relationships between the reduced folate levels in the CRC tissue after LV administration and the gene-expression levels of folate-metabolizing enzymes and folate transporters.

Methods

The subjects were 60 CRC patients, scheduled to undergo surgery. The control group (n = 30) did not receive LV. Three groups (n = 10 for each) received a single dose of oral LV at 25 mg, 4, 12 or 18 h before surgery (LV 4 h, LV 12 h or LV 18 h groups, respectively). The reduced folate levels in plasma and tissues were measured by high-performance liquid chromatography (HPLC) or a thymidylate synthase-FdUMP binding assay, respectively. The intratumoral expression levels of 34 genes were quantitatively evaluated with a real-time polymerase chain reaction (RT-PCR) assay.

Results

The reduced folate levels persisted for a longer period of time in the CRC tissue than in the plasma after LV administration. A multivariate logistic regression analysis revealed that high folylpolyglutamate synthase (FPGS) gene expression, low γ-glutamyl hydrolase (GGH) gene expression and low ATP-binding cassette sub-family C, number 1 (ABCC1) gene expression in CRC tissues were predictive factors for a high reduced folate level after LV administration.

Conclusions

The expression level of FPGS, GGH and ABCC1 in CRC tissues could predict the reduced folate level after LV administration, and these factors may determine the efficacy of LV treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Carmichael J, Popiela T, Radstone D, Falk S, Borner M, Oza A, Skovsgaard T, Munier S, Martin C (2002) Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20:3617–3627

    Article  CAS  PubMed  Google Scholar 

  2. Douillard JY, Hoff PM, Skillings JR, Eisenberg P, Davidson N, Harper P, Vincent MD, Lembersky BC, Thompson S, Maniero A, Benner SE (2002) Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20:3605–3616

    Article  CAS  PubMed  Google Scholar 

  3. Lembersky BC, Wieand HS, Petrelli NJ, O’Connell MJ, Colangelo LH, Smith RE, Seay TE, Giguere JK, Marshall ME, Jacobs AD, Colman LK, Soran A, Yothers G, Wolmark N (2006) Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol 24:2059–2064

    Article  CAS  PubMed  Google Scholar 

  4. Longley DB, Harkin DP, Johnston PG (2003) 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3:330–338

    Article  CAS  PubMed  Google Scholar 

  5. Priest DG, Schmitz JC, Bunni MA, Stuart RK (1991) Pharmacokinetics of leucovorin metabolites in human plasma as a function of dose administered orally and intravenously. J Natl Cancer Inst 83:1806–1812

    Article  CAS  PubMed  Google Scholar 

  6. Houghton JA, Williams LG, Cheshire PJ, Wainer IW, Jadaud P, Houghton PJ (1990) Influence of dose of [6RS]leucovorin on reduced folate pools and 5-fluorouracil-mediated thymidylate synthase inhibition in human colon adenocarcinoma xenografts. Cancer Res 50:3940–3946

    CAS  PubMed  Google Scholar 

  7. Houghton JA, Williams LG, de Graaf SS, Cheshire PJ, Rodman JH, Maneval DC, Wainer IW, Jadaud P, Houghton PJ (1990) Relationship between dose rate of [6RS]leucovorin administration, plasma concentrations of reduced folates, and pools of 5, 10-methylenetetrahydrofolates and tetrahydrofolates in human colon adenocarcinoma xenografts. Cancer Res 50:3493–3502

    CAS  PubMed  Google Scholar 

  8. Raghunathan K, Schmitz JC, Priest DG (1997) Impact of schedule on leucovorin potentiation of fluorouracil antitumor activity in dietary folic acid deplete mice. Biochem Pharmacol 53:1197–1202

    Article  CAS  PubMed  Google Scholar 

  9. Damle B, Ravandi F, Kaul S, Sonnichsen D, Ferreira I, Brooks D, Stewart D, Alberts D, Pazdur R (2001) Effect of food on the oral bioavailability of UFT and leucovorin in cancer patients. Clin Cancer Res 7:517–523

    CAS  PubMed  Google Scholar 

  10. Shirao K, Hoff PM, Ohtsu A, Loehrer PJ, Hyodo I, Wadler S, Wadleigh RG, O’Dwyer PJ, Muro K, Yamada Y, Boku N, Nagashima F, Abbruzzese JL (2004) Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV. J Clin Oncol 22:3466–3474

    Article  CAS  PubMed  Google Scholar 

  11. Schlemmer M, Kuehl M, Schalhorn A, Rauch J, Jauch KW, Hentrich M (2008) Tissue levels of reduced folates in patients with colorectal carcinoma after infusion of folinic Acid at various dose levels. Clin Cancer Res 14:7930–7934

    Article  CAS  PubMed  Google Scholar 

  12. Tsukioka S, Uchida J, Tsujimoto H, Nakagawa F, Sugimoto Y, Oka T, Kiniwa M (2009) Oral fluoropyrimidine S-1 combined with leucovorin is a promising therapy for colorectal cancer: evidence from a xenograft model of folate-depleted mice. Mol Med Rep 2:393–398

    CAS  Google Scholar 

  13. Etienne MC, Speziale N, Milano G (1993) HPLC of folinic acid diastereoisomers and 5-methyltetrahydrofolate in plasma. Clin Chem 39:82–86

    CAS  PubMed  Google Scholar 

  14. Belz S, Frickel C, Wolfrom C, Nau H, Henze G (1994) High-performance liquid chromatographic determination of methotrexate, 7-hydroxymethotrexate, 5-methyltetrahydrofolic acid and folinic acid in serum and cerebrospinal fluid. J Chromatogr B Biomed Appl 661:109–118

    Article  CAS  PubMed  Google Scholar 

  15. Etienne-Grimaldi MC, Francois E, Cardot JM, Renee N, Douillard JY, Gamelin E, Bennouna J, Chateau Y, Milano G (2007) A clinical pharmacokinetic analysis of tegafur-uracil (UFT) plus leucovorin given in a new twice-daily oral administration schedule. Clin Pharmacokinet 46:953–963

    Article  CAS  PubMed  Google Scholar 

  16. Suh JR, Herbig AK, Stover PJ (2001) New perspectives on folate catabolism. Annu Rev Nutr 21:255–282

    Article  CAS  PubMed  Google Scholar 

  17. Schneider E, Ryan TJ (2006) Gamma-glutamyl hydrolase and drug resistance. Clin Chim Acta 374:25–32

    Article  CAS  PubMed  Google Scholar 

  18. Sakamoto E, Tsukioka S, Oie S, Kobunai T, Tsujimoto H, Sakamoto K, Okayama Y, Sugimoto Y, Oka T, Fukushima M, Oka T (2008) Folylpolyglutamate synthase and gamma-glutamyl hydrolase regulate leucovorin-enhanced 5-fluorouracil anticancer activity. Biochem Biophys Res Commun 365:801–807

    Article  CAS  PubMed  Google Scholar 

  19. Kawakami K, Ooyama A, Ruszkiewicz A, Jin M, Watanabe G, Moore J, Oka T, Iacopetta B, Minamoto T (2008) Low expression of gamma-glutamyl hydrolase mRNA in primary colorectal cancer with the CpG island methylator phenotype. Br J Cancer 98:1555–1561

    Article  CAS  PubMed  Google Scholar 

  20. Assaraf YG (2006) The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis. Drug Resist Updat 9:227–246

    Article  CAS  PubMed  Google Scholar 

  21. Rayl EA, Moroson BA, Beardsley GP (1996) The human purH gene product, 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase. Cloning, sequencing, expression, purification, kinetic analysis, and domain mapping. J Biol Chem 271:2225–2233

    Article  CAS  PubMed  Google Scholar 

  22. Galivan J, Ryan TJ, Chave K, Rhee M, Yao R, Yin D (2000) Glutamyl hydrolase pharmacological role and enzymatic characterization. Pharmacol Ther 85:207–215

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan

    Sotaro Sadahiro, Toshiyuki Suzuki, Yuji Maeda, Akira Tanaka, Kyoji Ogoshi & Akemi Kamijo

  2. Department of Clinical Pharmacology, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan

    Chieko Murayama

  3. Taiho Pharmaceutical Co., Ltd, 224-2 Ebisuno Hiraishi, Kawauchi-cho, Tokushima, 771-0194, Japan

    Sayaka Tsukioka, Etsuko Sakamoto, Yousuke Fukui & Toshinori Oka

Authors
  1. Sotaro Sadahiro
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Toshiyuki Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yuji Maeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Akira Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kyoji Ogoshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Akemi Kamijo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Chieko Murayama
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Sayaka Tsukioka
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Etsuko Sakamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yousuke Fukui
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Toshinori Oka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sotaro Sadahiro.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sadahiro, S., Suzuki, T., Maeda, Y. et al. Molecular determinants of folate levels after leucovorin administration in colorectal cancer. Cancer Chemother Pharmacol 65, 735–742 (2010). https://doi.org/10.1007/s00280-009-1079-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-009-1079-5

Keywords

Search

Navigation